US National Institute of Allergy and Infectious Diseases (NIAID)

Vials labelled "Astra Zeneca COVID-19 Coronavirus Vaccine" and a syringe are seen in front of a displayed AstraZeneca logo, in this illustration photo taken March 14, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo
Coronavirus chronicle

AstraZeneca may have provided incomplete efficacy data from latest Covid-19 trial: NIAID

AstraZeneca said a day earlier that its Covid-19 vaccine developed with Oxford University was 79% effective in preventing symptomatic illness in a large trial in Chile, Peru and the United States